As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm ...

While Sarepta has now consented to the FDA’s request to stop selling Elevidys, the company’s brief standoff with the agency ...

Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

Sarepta Therapeutics (NASDAQ: SRPT) shares plunged 42% on Monday, June 16, following reports of a second patient death associated with its Duchenne muscular dystrophy gene therapy, Elevidys. In ...

Sarepta also preliminarily reported $513 million in second-quarter sales, missing projections for $529 million, according to FactSet. Elevidys brought in $282 million, which also lagged calls for ...

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.

This was driven by ELEVIDYS' label expansion, which included non-ambulatory patients in June 2024. Sarepta’s total net product revenues in Q1 were $611.5 million.

Sarepta reports a second fatal case of acute liver failure linked to Elevidys. Analyst cuts Sarepta’s rating due to uncertain safety and future revenue potential. Missed the rally? Learn exactly ...

Sarepta Therapeutics has temporarily suspended use of the gene therapy Elevidys in non-ambulatory patients with Duchenne muscular dystrophy (DMD) after a second patient taking the drug died from ...

For a broader perspective on Sarepta’s outlook, explore how other analysts view the stock. Price Action: SRPT stock is trading lower by 9.96% to $17.09 at last check Wednesday.

On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or ...